Boulder, CO, United States of America

Anil Modak

This inventor holds 4 USPTO granted patents and 1 EPO patent. Top assignee: Ribozyme Pharmaceuticals, Incorporated. Active years: 1997-2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anil Modak. Retrieved from https://idiyas.com/inventor/anil-modak

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 4

Forward Citations = 532(Granted Patents)


Company Filing History:


Years Active: 1997-2002

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Anil Modak: Innovator in Nucleic Acid Technologies

Introduction

Anil Modak is a prominent inventor based in Boulder, CO (US). He has made significant contributions to the field of nucleic acid technologies, holding a total of 4 patents. His work focuses on developing innovative solutions that enhance the stability and efficacy of nucleic acid molecules.

Latest Patents

Among his latest patents are two notable inventions: the "2′-deoxy-2′-alkylnucleotide containing nucleic acid" and the "2'-deoxy-2'-alkylnucleotide containing nucleic acid." Both patents are aimed at stabilizing enzymatic nucleic acid molecules and antisense molecules, showcasing his expertise in this specialized area.

Career Highlights

Anil Modak is currently associated with Ribozyme Pharmaceuticals, Incorporated, where he continues to push the boundaries of nucleic acid research. His work has been instrumental in advancing the understanding and application of nucleic acids in various therapeutic contexts.

Collaborations

He collaborates with talented individuals such as Nassim Usman and Alexander Karpeisky, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Anil Modak's contributions to nucleic acid technologies highlight his role as a key innovator in the field. His patents and ongoing research efforts continue to pave the way for advancements in therapeutic applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…